NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free GOSS Stock Alerts $0.65 -0.06 (-8.23%) (As of 12:40 PM ET) Add Compare Share Share Today's Range$0.63▼$0.6950-Day Range$0.71▼$1.5152-Week Range$0.45▼$1.88Volume1.12 million shsAverage Volume1.18 million shsMarket Capitalization$146.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Gossamer Bio alerts: Email Address Gossamer Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside1,059.1% Upside$7.65 Price TargetShort InterestBearish4.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$39,682 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.75) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.61 out of 5 starsMedical Sector263rd out of 907 stocksPharmaceutical Preparations Industry111th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.93% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Gossamer Bio has recently increased by 3.25%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 1.2 News and Social Media Coverage News SentimentGossamer Bio has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,682.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.75) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Gossamer Bio Stock (NASDAQ:GOSS)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More GOSS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOSS Stock News HeadlinesMarch 29, 2024 | insidertrades.comGossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Sells 23,172 SharesMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment LandscapeApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 21, 2024 | investing.comGossamer Bio EVP sells over $5,000 in company stockMarch 21, 2024 | investing.comGossamer Bio executive sells over $5,000 in company stockMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)March 16, 2024 | ca.finance.yahoo.comGOSS Apr 2024 1.500 putMarch 16, 2024 | finance.yahoo.comGOSS Apr 2024 1.000 putApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 13, 2024 | theguardian.comTara Rae Moss: ‘So many doctors in different continents told me that I would never recover’March 12, 2024 | finance.yahoo.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsMarch 12, 2024 | businesswire.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D.March 11, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Gossamer Bio (GOSS)March 7, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment MarketMarch 6, 2024 | markets.businessinsider.comGossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market ExpansionMarch 5, 2024 | investorplace.comGOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023March 5, 2024 | markets.businessinsider.comGossamer Bio Posts Narrower Loss In Q4 - Quick FactsMarch 5, 2024 | businesswire.comGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 22, 2024 | benzinga.comGossamer Bio Stock (NASDAQ:GOSS) Dividends: History, Yield and DatesFebruary 16, 2024 | investing.comGossamer Bio Inc (GOSS)February 8, 2024 | finance.yahoo.com7 Micro-Cap Stocks That Could Majorly Surprise InvestorsFebruary 3, 2024 | thestreet.comGossamer Bio Inc.January 22, 2024 | insidermonkey.com5 Small-Cap Stocks with High PotentialJanuary 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Neurogene (NGNE) and Gossamer Bio (GOSS)January 8, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To KnowDecember 21, 2023 | markets.businessinsider.comSeralutinib’s Promising Efficacy and Market Potential Reinforce Buy RatingDecember 20, 2023 | benzinga.comGossamer Bio Stock (NASDAQ:GOSS) Insider TradesSee More Headlines Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$7.65 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+980.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-944.79% Return on Assets-67.76% Debt Debt-to-Equity Ratio3.14 Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book2.53Miscellaneous Outstanding Shares225,580,000Free Float204,152,000Market Cap$159.78 million OptionableOptionable Beta1.71 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Faheem Hasnain (Age 66)Co-Founder, CEO, President & Chairman Comp: $902.52kMr. Bryan Giraudo (Age 49)COO & CFO Comp: $690.59kDr. Richard Aranda M.D. (Age 63)Chief Medical Officer Comp: $625.24kMr. Christian Waage (Age 57)Executive Vice President of Technical Operations & Administration Comp: $583.16kMr. Jeff BoernekeGeneral Counsel & SecretaryMs. Deanna WeberSenior Vice President of Human ResourcesMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMs. Caryn L. Peterson (Age 65)Executive Vice President of Regulatory Affairs Mr. Matt CravetsSenior Vice President of BiometricsDr. Lisa Elizabeth Nolan Ph.D. (Age 62)MD & President of Gossamer Bio Ireland More ExecutivesKey CompetitorsscPharmaceuticalsNASDAQ:SCPHProQR TherapeuticsNASDAQ:PRQRGreenwich LifeSciencesNASDAQ:GLSIAEON BiopharmaNASDAQ:AEONTelomir PharmaceuticalsNASDAQ:TELOView All CompetitorsInsiders & InstitutionsSivia Capital Partners LLCBought 24,568 shares on 4/19/2024Ownership: 0.011%Faheem HasnainSold 23,172 sharesTotal: $26,879.52 ($1.16/share)Bryan GiraudoSold 6,430 sharesTotal: $7,458.80 ($1.16/share)Richard ArandaSold 4,018 sharesTotal: $5,343.94 ($1.33/share)Madison Avenue Partners LPSold 1,075,796 shares on 2/16/2024Ownership: 2.242%View All Insider TransactionsView All Institutional Transactions GOSS Stock Analysis - Frequently Asked Questions Should I buy or sell Gossamer Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GOSS shares. View GOSS analyst ratings or view top-rated stocks. What is Gossamer Bio's stock price target for 2024? 5 brokers have issued 12-month price objectives for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $15.00. On average, they anticipate the company's share price to reach $7.65 in the next year. This suggests a possible upside of 1,059.1% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts. How have GOSS shares performed in 2024? Gossamer Bio's stock was trading at $0.9125 at the beginning of the year. Since then, GOSS shares have decreased by 27.7% and is now trading at $0.66. View the best growth stocks for 2024 here. When is Gossamer Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our GOSS earnings forecast. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA). When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Sivia Capital Partners LLC (0.01%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Richard Aranda and Waage Christian. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOSS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
